TNB Tech Minute: Trump Signs Executive Order to Increase Federal Oversight of AI

**SPEAKER_1** (0:00)
This podcast is brought to you by Atlassian Rovo. Tired of 10 different AI tools creating knowledge gaps? Rovo takes your team from AI novice to AI native by working where you already work, like JIRA and Confluence, so your team stays aligned.

**Julie Chang** (0:17)
Here's your afternoon TNB Tech Minute for Tuesday, June 2nd. I'm Julie Chang for The Wall Street Journal. President Trump signed an executive order today asking AI companies to give the administration access to powerful models 30 days before public release. A previous version of the order had set a 90-day voluntary review period, but was postponed last month. The order, which aims to strengthen federal oversight of the tech, directs national security and cyber officials to collaborate with tech firms to address vulnerabilities identified by models like Anthropics' mythos. The administration also approved Anthropics' expansion of mythos access to roughly 150 organizations around the world to identify software bugs and patch vulnerabilities. The White House previously opposed the move because of security concerns.
The AI buildout has sent memory prices soaring, creating a supply crunch that will only get worse next year. That's according to Taiwan-based research firm TrendForce. The firm says the top three major memory chipmakers, Samsung Electronics, SK Hynex and Micron, will likely increase high bandwidth memory or HBM prices for 2027 Surging prices of standard memory have temporarily made locked-in HBM contracts less profitable, pushing manufacturers to negotiate higher rates for next-generation technology. TrendForce says continued appetite for AI infrastructure will keep HBM demand high.
Finally, New Limit, a longevity startup co-founded by Coinbase CEO Brian Armstrong, completed a fundraising that brings its valuation to more than $3 billion.
The company says that's more than triple what it was a year ago. New Limit is focused on reversing cellular aging, but doesn't have any products on the market yet. Its first drug, targeting alcohol-related liver disease, will begin human studies next year. New Limit is part of a growing trend of billionaire-backed longevity ventures, including Sam Altman's $180 million investment in retro biosciences, and the Jeff Bezos is funded Altos Labs, which has raised nearly $6 billion since its 2022 launch. That's it for your TMB Tech Minutes. We'll have another Quick Tech Update in the morning.

**SPEAKER_1** (2:42)
This podcast is brought to you by Atlassian Rovo. Tired of 10 different AI tools creating knowledge gaps? Rovo takes your team from AI novice to AI native by working where you already work, like JIRA and Confluence, so your team stays aligned.